PLCB1 and myelodysplastic syndrome: Interestingly, expression of nuclear PLCβ1 is increased during demethylation therapy in MDS patients and is associated with a good response to the drug (69) while monoallelic deletion of PLCβ1 is associated with poor prognosis of MDS patients (70).